Vireo Growth (VREOF) Other Non Operating Income (2020 - 2026)
Vireo Growth (VREOF) posted Other Non Operating Income of $100000.0 for Q1 2026, up 106.5% sequentially from -$1.5 million in Q4 2025, and down 87.5% YoY from $800000.0 in Q1 2025.
Vireo Growth (VREOF) Other Non Operating Income (2020 - 2026) Analysis & Trends
Vireo Growth has reported Other Non Operating Income for 7 years, with the latest figure at $100000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 87.5% year-over-year to $100000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$862849.0 (down 299.87% YoY) and the FY2025 annual result came in at -$172811.0, down 118.2% from the prior year.
- Other Non Operating Income rose to $100000.0 in Q1 2026 per VREOF's latest filing, from -$1.5 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $5.8 million in Q2 2023 and troughed at -$2.9 million in Q4 2024.
- A 5-year average of $580896.5 and a median of $345824.0 in 2023 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Other Non Operating Income surged 7105.44% in 2023, then tumbled 285.63% in 2024.
- Over 5 years, Other Non Operating Income stood at $45518.0 in 2022, then soared by 3370.77% to $1.6 million in 2023, then sank by 285.63% to -$2.9 million in 2024, then soared by 47.55% to -$1.5 million in 2025, then surged by 106.5% to $100000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $100000.0, -$1.5 million, and $983080.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | -1.54 Mn |
| Sep 30, 2025 | 983,080.00 |
| Jun 30, 2025 | -407,673.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | -2.93 Mn |
| Sep 30, 2024 | 970,850.00 |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.58 Mn |
| Sep 30, 2023 | 345,824.00 |
| Jun 30, 2023 | 5.80 Mn |
| Mar 31, 2023 | 22,313.00 |
| Dec 31, 2022 | 45,518.00 |
| Sep 30, 2022 | 79,750.00 |
| Jun 30, 2022 | -82,769.00 |
| Mar 31, 2022 | 1.20 Mn |
| Dec 31, 2021 | -278,260.00 |
| Sep 30, 2021 | 75,018.00 |
| Jun 30, 2021 | -98,055.00 |